Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
SHANGHAI, Aug. 24, 2022 /PRNewswire/ — Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing…